Overview

A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

Status:
Completed

Trial end date:
2009-07-01

Target enrollment:

Participant gender:

Summary

This study will compare the benefits of exenatide once weekly treatment to those achieved by the approved antidiabetic therapies sitagliptin and pioglitazone in subjects whose type 2 diabetes is managed with metformin therapy alone. The safety and tolerability of the three treatment regimens will also be compared.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Eli Lilly and Company

Treatments:

2,4-thiazolidinedione
Exenatide
Metformin
Pioglitazone
Sitagliptin Phosphate